Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMGN PFE LLY MRK REGN JNJ BMY VRTX GILD BIIB

| Held by: VTI IJH VB VBR VXF XMHQ MDY IBB IJK SPMD

Index	-	P/E	18.40	EPS (ttm)	26.39	Insider Own	3.52%	Shs Outstand	42.90M	Perf Week	3.38%
Market Cap	20.90B	Forward P/E	15.89	EPS next Y	30.55	Insider Trans	-42.10%	Shs Float	41.54M	Perf Month	-3.64%
Enterprise Value	18.13B	PEG	1.53	EPS next Q	7.16	Inst Own	96.23%	Short Float	4.30%	Perf Quarter	8.47%
Income	1.27B	P/S	6.68	EPS this Y	11.67%	Inst Trans	-3.82%	Short Ratio	4.33	Perf Half Y	62.10%
Sales	3.13B	P/B	3.16	EPS next Y	11.04%	ROA	17.57%	Short Interest	1.78M	Perf YTD	-0.39%
Book/sh	153.61	P/C	7.55	EPS next 5Y	10.37%	ROE	20.04%	52W High	519.99 -6.66%	Perf Year	37.04%
Cash/sh	64.28	P/FCF	18.63	EPS past 3/5Y	34.80% -	ROIC	19.30%	52W Low	266.98 81.80%	Perf 3Y	86.68%
Dividend Est.	-	EV/EBITDA	11.34	Sales past 3/5Y	19.52% 14.71%	Gross Margin	88.59%	Volatility	2.22% 2.16%	Perf 5Y	188.53%
Dividend TTM	-	EV/Sales	5.80	EPS Y/Y TTM	17.16%	Oper. Margin	48.46%	ATR (14)	10.76	Perf 10Y	294.02%
Dividend Ex-Date	-	Quick Ratio	6.07	Sales Y/Y TTM	13.50%	Profit Margin	40.65%	RSI (14)	55.11	Recom	1.60
Dividend Gr. 3/5Y	- -	Current Ratio	6.40	EPS Q/Q	12.12%	SMA20	2.30%	Beta	0.85	Target Price	540.27
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	6.76%	SMA50	-0.26%	Rel Volume	0.72	Prev Close	478.93
Employees	1305	LT Debt/Eq	0.00	Earnings	Oct 29 BMO	SMA200	25.30%	Avg Volume	412.40K	Price	485.36
IPO	Jun 17, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.14% -1.64%	Trades		Volume	297,127	Change	1.34%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Underweight	$414
Sep-26-25	Initiated	RBC Capital Mkts	Outperform	$569
Jun-02-25	Initiated	Cantor Fitzgerald	Overweight	$405
Apr-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-21-25	Upgrade	BofA Securities	Underperform → Neutral	$314
Jul-11-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$310 → $321
Feb-12-24	Upgrade	Goldman	Sell → Neutral	$213 → $215
Feb-05-24	Initiated	Leerink Partners	Outperform	$330
Dec-08-23	Initiated	Wells Fargo	Overweight	$309
Dec-06-22	Initiated	UBS	Buy	$320
Dec-05-22	Initiated	Goldman	Sell	$230
Oct-11-22	Initiated	Morgan Stanley	Overweight	$288
Sep-20-22	Reiterated	BofA Securities	Underperform
Sep-19-22	Resumed	Wedbush	Outperform	$263
Feb-11-22	Initiated	BTIG Research	Neutral
Jul-14-21	Upgrade	Argus	Hold → Buy	$205
Apr-26-21	Resumed	Credit Suisse	Outperform	$196
Feb-01-21	Upgrade	H.C. Wainwright	Neutral → Buy	$125 → $195
Sep-14-20	Resumed	JP Morgan	Overweight	$142
Jun-25-20	Reiterated	H.C. Wainwright	Neutral	$85 → $125

Show Previous Ratings

Today 11:04AM	Merck's Subdued 2026 Outlook: What it Means After Q4 Results? (Zacks)
Jan-29-26 10:32PM	A Look Back at Therapeutics Stocks' Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack (StockStory)
Jan-28-26 10:15AM	Merck's Non-Oncology Drugs Q4 Performance: What to Expect (Zacks)
Jan-27-26 10:33PM	Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) (StockStory)
Jan-26-26 08:55AM	United Therapeutics Reports Early Success For External Liver Support In Acute Failure (Benzinga)
07:00AM	Loading…
07:00AM	United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP in Patients with Acute Liver Failure (Business Wire)
Jan-22-26 07:00AM	United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors (Business Wire)
Jan-19-26 05:17PM	United Therapeutics Corporation (UTHR): A Bull Case Theory (Insider Monkey)
Jan-16-26 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Jan-15-26 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Jan-13-26 10:39AM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
Jan-12-26 03:57PM	6 stocks and ETFs that these unsung market heroes see outperforming in 2026 (MarketWatch)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Jan-08-26 11:40AM	UTHR or MDGL: Which Is the Better Value Stock Right Now? (Zacks)
Jan-07-26 11:40AM	UTHR vs. ZTS: Which Stock Is the Better Value Option? (Zacks)
07:00AM	Loading…
Jan-05-26 07:00AM	United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Dec-30-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
Dec-15-25 09:50AM	MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH (Zacks)
Dec-11-25 09:50AM	Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock (Zacks)
Dec-10-25 11:30AM	Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report? (Zacks)
09:40AM	Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term (Zacks)
Dec-09-25 12:26PM	This Gold Stock Hits A High, With Miner Poised For Huge Swing To Profit (Investor's Business Daily)
09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
Dec-05-25 11:30AM	Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
11:20AM	Can Merck's New Products Aid Growth as Keytruda LOE Test Looms? (Zacks)
Dec-03-25 07:19AM	Flurry of Bullish Inflows Sends United Therapeutics Higher (FX Empire)
Nov-21-25 12:04PM	United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base (Investor's Business Daily)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:45AM	Loading…
Nov-20-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks)
Nov-19-25 10:52AM	Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study (Zacks)
Nov-12-25 09:50AM	Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term (Zacks)
Nov-09-25 11:02PM	3 Reasons Investors Love United Therapeutics (UTHR) (StockStory)
Nov-05-25 09:40AM	Here's Why United Therapeutics (UTHR) is a Strong Value Stock (Zacks)
12:35AM	The 5 Most Interesting Analyst Questions From United Therapeutics's Q3 Earnings Call (StockStory)
Nov-04-25 09:45AM	Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term (Zacks)
07:00AM	United Therapeutics Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 07:00AM	United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease (Business Wire)
Oct-30-25 03:48PM	United Therapeutics Corp (UTHR) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:40AM	MKKGY vs. UTHR: Which Stock Is the Better Value Option? (Zacks)
01:38AM	UTHR Q3 Deep Dive: Clinical Pipeline Advances and High-Dose Product Launches Drive Outlook (StockStory)
Oct-29-25 04:14PM	United Therapeutics Rockets 10% On Growing Enthusiasm For Its Top Drug (Investor's Business Daily) +9.63%
01:11PM	Why Is United Therapeutics (UTHR) Stock Soaring Today (StockStory)
11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
09:55AM	The Mixed Results For United Therapeutics' Bread-And-Butter Drug (Investor's Business Daily)
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q3 Earnings: A Look at Key Metrics (Zacks)
08:51AM	United Therapeutics Dips As Bread-And-Butter Drug Comes Up Short (Investor's Business Daily)
07:40AM	United Therapeutics (UTHR) Beats Q3 Earnings Estimates (Zacks)
06:48AM	United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
06:43AM	United Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results (Business Wire)
Oct-27-25 11:17PM	United Therapeutics (UTHR) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 10:05AM	Merck's Non-Oncology Drugs Q3 Performance: What to Expect (Zacks)
Oct-23-25 10:00AM	Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-22-25 10:00AM	United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Oct-16-25 03:51PM	Jefferies Reiterates Buy Rating on United Therapeutics (UTHR) Amid Patent Case (Insider Monkey)
Oct-15-25 07:00AM	United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025 (Business Wire)
Oct-13-25 07:00AM	United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting (Business Wire)
Oct-01-25 10:40AM	Is IPF the Next Big Market Opportunity for United Therapeutics? (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Sep-30-25 04:38PM	Top Stock Reports for NextEra Energy, U.S. Bancorp and Air Products & Chemicals (Zacks)
Sep-26-25 09:46AM	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls (The Fly)
Sep-19-25 11:53AM	Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE? (Zacks)
07:00AM	United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso in Idiopathic Pulmonary Fibrosis (Business Wire)
12:46AM	1 Momentum Stock to Target This Week and 2 We Brush Off (StockStory)
12:03AM	3 Big Reasons to Love United Therapeutics (UTHR) (StockStory)
Sep-16-25 07:00AM	United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum (Business Wire)
Sep-12-25 07:00AM	United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress (Business Wire)
Sep-11-25 11:30AM	Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-10-25 02:46PM	United Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last Week (Investor's Business Daily)
Sep-03-25 01:48PM	UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals (Zacks)
09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
08:52AM	Pharma, Opendoor, Tesla: Trending Stocks (Yahoo Finance Video)
06:30AM	Lung Disease Breakthrough Boosts United Therapeutics and its Rivals (The Daily Upside)
Sep-02-25 04:09PM	Why United Therapeutics Catapulted 33%, Pulling Insmed, Liquidia With It (Investor's Business Daily) +32.83%
09:34AM	Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It (Investor's Business Daily)
07:00AM	United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis (Business Wire)
Aug-29-25 11:30AM	Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report? (Zacks)
07:00AM	United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-13-25 12:05AM	5 Insightful Analyst Questions From United Therapeutics's Q2 Earnings Call (StockStory)
Aug-12-25 11:40PM	UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty (StockStory)
04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
Aug-11-25 04:15PM	3D Systems Reports Second Quarter 2025 Financial Results (GlobeNewswire)
11:32AM	Merck's Narrowed 2025 Sales View: What it Means After Q2 Results? (Zacks)
Aug-01-25 07:00AM	United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program (Business Wire) +7.13%
Jul-31-25 10:15AM	UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y (Zacks)
Jul-30-25 09:45AM	Here's Why United Therapeutics (UTHR) is a Strong Growth Stock (Zacks) -5.25%
09:30AM	Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics (Zacks)
07:35AM	United Therapeutics (UTHR) Misses Q2 Earnings Estimates (Zacks)
06:46AM	United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates (StockStory)
06:36AM	United Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results (Business Wire)
Jul-28-25 11:13PM	What To Expect From United Therapeutics's (UTHR) Q2 Earnings (StockStory)
10:00AM	Earnings Preview: Ardelyx (ARDX) Q2 Earnings Expected to Decline (Zacks)
02:07AM	Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT (Insider Monkey)
Jul-25-25 10:42PM	United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial (Insider Monkey)
Jul-24-25 09:50AM	United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 05 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Feb 05 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Feb 05 '26	Sale	483.25	8,300	4,010,940	36,781	Feb 05 04:31 PM
PAUL MAHON	Officer	Feb 05 '26	Proposed Sale	483.25	8,300	4,010,939		Feb 05 04:03 PM
MALCOLM JAN	Director	Feb 03 '26	Sale	474.23	50	23,712	270	Feb 03 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 02 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Feb 03 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Feb 02 '26	Sale	470.95	22,500	10,596,429	0	Feb 03 04:31 PM
JAN MALCOLM	Director	Feb 03 '26	Proposed Sale	474.23	50	23,712		Feb 03 04:03 PM
Michael Benkowitz	Officer	Feb 02 '26	Proposed Sale	469.49	90,000	42,254,100		Feb 02 04:29 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 26 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Option Exercise	146.03	7,875	1,149,986	7,875	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 26 '26	Sale	471.91	22,500	10,617,932	0	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Sale	464.66	7,875	3,659,182	0	Jan 28 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 20 '26	Sale	464.66	14,625	6,795,627	0	Jan 28 04:30 PM
MALCOLM JAN	Director	Jan 16 '26	Sale	460.98	50	23,049	320	Jan 20 04:30 PM
JAN MALCOLM	Director	Jan 20 '26	Proposed Sale	460.98	50	23,049		Jan 20 04:02 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 15 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Jan 15 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 15 '26	Sale	469.89	8,300	3,900,122	36,781	Jan 15 04:32 PM
PAUL MAHON	Officer	Jan 15 '26	Proposed Sale	469.89	8,300	3,900,122		Jan 15 04:06 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 12 '26	Option Exercise	127.65	22,500	2,872,226	14,625	Jan 13 05:10 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 12 '26	Sale	479.51	22,500	10,788,876	0	Jan 13 05:10 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Option Exercise	117.76	14,625	1,722,240	14,625	Jan 07 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Sale	487.38	14,625	7,127,877	0	Jan 07 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Option Exercise	146.03	7,875	1,149,986	7,875	Jan 07 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Jan 05 '26	Sale	487.38	7,875	3,838,085	0	Jan 07 04:30 PM
CAUSEY CHRISTOPHER	Director	Jan 06 '26	Option Exercise	119.76	1,000	119,760	5,190	Jan 06 04:31 PM
CAUSEY CHRISTOPHER	Director	Jan 06 '26	Sale	510.00	1,000	510,000	4,190	Jan 06 04:31 PM
MALCOLM JAN	Director	Jan 05 '26	Sale	495.01	50	24,750	370	Jan 06 04:31 PM
CHRISTOPHER CAUSEY	Director	Jan 06 '26	Proposed Sale	510.00	1,000	510,000		Jan 06 04:07 PM
JAN MALCOLM	Director	Jan 06 '26	Proposed Sale	495.01	50	24,750		Jan 06 04:06 PM
CAUSEY CHRISTOPHER	Director	Jan 02 '26	Option Exercise	119.76	1,000	119,760	5,190	Jan 05 04:59 PM
CAUSEY CHRISTOPHER	Director	Jan 02 '26	Sale	500.01	1,000	500,015	4,190	Jan 05 04:59 PM
Michael Benkowitz	Officer	Jan 05 '26	Proposed Sale	496.72	90,000	44,704,800		Jan 05 04:39 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '26	Option Exercise	146.03	8,300	1,212,049	45,081	Jan 02 04:30 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Jan 02 '26	Sale	485.43	8,300	4,029,076	36,781	Jan 02 04:30 PM
CHRISTOPHER CAUSEY	Director	Jan 02 '26	Proposed Sale	500.01	1,000	500,015		Jan 02 04:22 PM
PAUL MAHON	Officer	Jan 02 '26	Proposed Sale	485.43	8,300	4,029,076		Jan 02 04:12 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 29 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Dec 30 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 29 '25	Sale	502.79	22,500	11,312,710	0	Dec 30 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 24 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 29 04:31 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 24 '25	Sale	513.18	11,000	5,644,954	36,781	Dec 29 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 22 '25	Option Exercise	146.03	7,875	1,149,986	7,875	Dec 29 04:30 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 22 '25	Sale	514.35	22,500	11,572,963	0	Dec 29 04:30 PM
PAUL MAHON	Officer	Dec 24 '25	Proposed Sale	513.18	11,000	5,644,954		Dec 29 09:37 AM
MALCOLM JAN	Director	Dec 23 '25	Sale	512.12	50	25,606	420	Dec 23 04:33 PM
SULLIVAN LOUIS W	Director	Dec 22 '25	Option Exercise	204.93	5,950	1,219,339	5,950	Dec 23 04:33 PM
SULLIVAN LOUIS W	Director	Dec 22 '25	Sale	512.13	5,950	3,047,201	0	Dec 23 04:33 PM
LOUIS WADE SULLIVAN REVOCABLE	Affiliate	Dec 22 '25	Proposed Sale	512.13	5,950	3,047,200		Dec 22 05:13 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 19 '25	Proposed Sale	507.07	2,000	1,014,143		Dec 19 05:39 PM
Thompson Tommy G	Director	Dec 18 '25	Option Exercise	101.80	910	92,638	9,390	Dec 19 04:31 PM
Thompson Tommy G	Director	Dec 18 '25	Sale	500.59	910	455,533	8,480	Dec 19 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 17 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 18 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 19 '25	Option Exercise	120.26	2,000	240,520	2,130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 18 '25	Sale	508.87	4,000	2,035,488	130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 17 '25	Sale	501.04	4,000	2,004,147	130	Dec 19 04:30 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 19 '25	Sale	507.07	2,000	1,014,143	130	Dec 19 04:30 PM
TOMMY THOMPSON	Director	Dec 18 '25	Proposed Sale	500.59	910	455,533		Dec 18 04:09 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 18 '25	Proposed Sale	508.87	4,000	2,035,488		Dec 18 04:00 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 17 '25	Proposed Sale	501.04	4,000	2,004,152		Dec 17 04:52 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 15 '25	Option Exercise	146.03	3,517	513,588	11,659	Dec 16 05:09 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 15 '25	Sale	495.36	3,517	1,742,193	8,142	Dec 16 05:09 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 15 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 16 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 16 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 16 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 15 '25	Sale	494.72	4,000	1,978,869	130	Dec 16 05:08 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 16 '25	Sale	493.45	4,000	1,973,820	130	Dec 16 05:08 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 15 '25	Option Exercise	244.05	22,500	5,491,040	14,625	Dec 16 04:33 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 15 '25	Sale	496.30	22,500	11,166,722	0	Dec 16 04:33 PM
PATUSKY CHRISTOPHER	Director	Dec 15 '25	Option Exercise	101.80	1,000	101,800	2,490	Dec 16 04:30 PM
PATUSKY CHRISTOPHER	Director	Dec 15 '25	Sale	495.95	1,000	495,954	1,490	Dec 16 04:30 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 16 '25	Proposed Sale	493.45	4,000	1,973,820		Dec 16 04:01 PM
CHRISTOPHER PATUSKY	Director	Dec 15 '25	Proposed Sale	495.95	1,000	495,954		Dec 15 05:45 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 15 '25	Proposed Sale	494.72	4,000	1,978,869		Dec 15 04:57 PM
MALCOLM JAN	Director	Dec 11 '25	Sale	482.98	50	24,149	470	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Option Exercise	146.03	11,000	1,606,330	47,781	Dec 12 04:32 PM
MAHON PAUL A	EVP & GENERAL COUNSEL	Dec 11 '25	Sale	484.67	11,000	5,331,316	36,781	Dec 12 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 12 '25	Sale	490.70	4,000	1,962,783	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 11 '25	Sale	483.97	4,000	1,935,879	130	Dec 12 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 12 '25	Proposed Sale	490.70	4,000	1,962,783		Dec 12 04:04 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 11 '25	Proposed Sale	483.97	4,000	1,935,879		Dec 11 04:10 PM
PAUL MAHON	Officer	Dec 11 '25	Proposed Sale	484.67	11,000	5,331,316		Dec 11 04:06 PM
Mesa Nilda	Director	Dec 09 '25	Sale	481.63	187	90,065	5,286	Dec 10 04:54 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 10 '25	Sale	480.05	4,000	1,920,191	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 09 '25	Sale	478.30	4,000	1,913,184	130	Dec 10 04:53 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 10 '25	Proposed Sale	480.05	4,000	1,920,190		Dec 10 03:52 PM
NILDA MESA	Director	Dec 09 '25	Proposed Sale	481.63	187	90,065		Dec 09 06:01 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Option Exercise	146.03	21,000	3,066,630	29,142	Dec 09 04:54 PM
EDGEMOND JAMES	CFO AND TREASURER	Dec 08 '25	Sale	478.60	21,000	10,050,597	8,142	Dec 09 04:54 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Option Exercise	244.05	22,500	5,491,040	14,625	Dec 09 04:31 PM
BENKOWITZ MICHAEL	PRESIDENT AND COO	Dec 08 '25	Sale	478.58	22,500	10,768,000	0	Dec 09 04:31 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 09 '25	Proposed Sale	478.30	4,000	1,913,184		Dec 09 03:47 PM
ROTHBLATT MARTINE A	FOUNDER, CHAIRPERSON, AND CHIE	Dec 08 '25	Proposed Sale	484.23	4,000	1,936,936		Dec 08 06:25 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 08 '25	Sale	484.23	4,000	1,936,936	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 05 '25	Sale	483.28	4,000	1,933,120	130	Dec 08 04:32 PM
ROTHBLATT MARTINE A	Chairperson & CEO	Dec 03 '25	Option Exercise	120.26	4,000	481,040	4,130	Dec 05 04:54 PM

Open in Screener

ARES

Ares Management Corp

Feb 06 • 04:00PM ET

130.46

+8.59 7.05 %

Financial • Asset Management • USA • NYSE

ARES Ares Management Corp daily Stock Chart

Peers: BX APO KKR CG BAM WELL BXMT MC HLNE KYN

| Held by: VTI VOO VO VUG IVV SPY VOT XLF IWP VYM

Index	S&P 500	P/E	72.59	EPS (ttm)	1.80	Insider Own	5.97%	Shs Outstand	220.34M	Perf Week	-12.83%
Market Cap	42.64B	Forward P/E	16.80	EPS next Y	7.77	Insider Trans	-48.90%	Shs Float	207.19M	Perf Month	-23.62%
Enterprise Value	58.03B	PEG	0.74	EPS next Q	1.45	Inst Own	91.78%	Short Float	4.09%	Perf Quarter	-14.87%
Income	394.31M	P/S	6.60	EPS this Y	36.65%	Inst Trans	1.15%	Short Ratio	2.54	Perf Half Y	-30.22%
Sales	6.46B	P/B	6.42	EPS next Y	19.38%	ROA	2.37%	Short Interest	8.47M	Perf YTD	-19.28%
Book/sh	20.31	P/C	28.43	EPS next 5Y	22.83%	ROE	18.64%	52W High	195.26 -33.19%	Perf Year	-31.21%
Cash/sh	4.59	P/FCF	15.09	EPS past 3/5Y	30.89% 17.58%	ROIC	2.30%	52W Low	110.63 17.92%	Perf 3Y	54.10%
Dividend Est.	5.40 (4.14%)	EV/EBITDA	28.50	Sales past 3/5Y	27.34% 31.30%	Gross Margin	78.50%	Volatility	8.84% 4.37%	Perf 5Y	186.31%
Dividend TTM	4.48 (3.43%)	EV/Sales	8.98	EPS Y/Y TTM	-12.79%	Oper. Margin	27.77%	ATR (14)	7.32	Perf 10Y	1030.13%
Dividend Ex-Date	Mar 17, 2026	Quick Ratio	0.50	Sales Y/Y TTM	53.25%	Profit Margin	6.10%	RSI (14)	32.01	Recom	1.79
Dividend Gr. 3/5Y	22.45% 22.87%	Current Ratio	0.50	EPS Q/Q	-80.79%	SMA20	-15.54%	Beta	1.56	Target Price	188.25
Payout	228.52%	Debt/Eq	2.84	Sales Q/Q	27.68%	SMA50	-19.59%	Rel Volume	2.03	Prev Close	121.87
Employees	3200	LT Debt/Eq	2.84	Earnings	Feb 05 BMO	SMA200	-21.44%	Avg Volume	3.33M	Price	130.46
IPO	May 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.00% 0.75%	Trades		Volume	6,748,721	Change	7.05%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Upgrade	Deutsche Bank	Hold → Buy
Dec-11-25	Resumed	UBS	Neutral	$201
Oct-14-25	Upgrade	Oppenheimer	Perform → Outperform	$180
Oct-03-25	Initiated	BMO Capital Markets	Market Perform	$156
Jul-28-25	Initiated	Raymond James	Mkt Perform
May-15-25	Downgrade	Oppenheimer	Outperform → Perform
Apr-16-25	Upgrade	Oppenheimer	Perform → Outperform	$159
Apr-08-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$165
Jan-27-25	Resumed	Barclays	Overweight	$224
Dec-20-24	Upgrade	Keefe Bruyette	Mkt Perform → Outperform	$166 → $202
Dec-12-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$212
Sep-12-24	Initiated	Wells Fargo	Equal Weight	$156
Aug-27-24	Initiated	Redburn Atlantic	Neutral	$140
Jun-13-24	Downgrade	Deutsche Bank	Buy → Hold	$176 → $132
May-28-24	Initiated	Deutsche Bank	Buy	$176
May-07-24	Initiated	TD Cowen	Buy	$154
Jan-09-24	Downgrade	Jefferies	Buy → Hold	$122
Oct-05-23	Initiated	Wolfe Research	Outperform	$133
Jul-10-23	Downgrade	Keefe Bruyette	Outperform → Mkt Perform	$99 → $98
Jun-12-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$99 → $93

Show Previous Ratings

Today 04:38PM	Deal Dispatch: SpaceX Ties Up With xAI, Kirin Sells Four Roses Bourbon, Billionaire's Mining Merger Collapses (Benzinga) +7.05%
03:07AM	Ares Management Q4 Earnings Call Highlights (MarketBeat)
12:32AM	ARES Q4 Deep Dive: Private Credit Growth and Software Exposure Under Investor Scrutiny (StockStory)
Feb-05-26 06:00PM	Ares Management Corp (ARES) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Expansion (GuruFocus.com) -11.19%
04:18PM	Ares Sees Investment Opportunities in AI Disruption (The Wall Street Journal)
03:19PM	Loading…
03:19PM	Blue Owl Dismisses Software Debt Fears After Shares Slide (The Wall Street Journal)
02:45PM	Analyst Report: Ares Management Corporation (Morningstar Research)
01:20PM	Ares Management Stock Falls as Q4 Earnings Miss, Expenses Rise Y/Y (Zacks)
11:55AM	'I can do the math': Wall Street's private credit giants try to calm AI fears amid steep software sell-off (Yahoo Finance)
11:55AM	'I can do it in math': Wall Street's private credit giants try to calm AI fears amid steep software sell-off (Yahoo Finance)
10:58AM	Ares Is Well-Hedged Against AI Change, Arougheti Says (Bloomberg)
10:52AM	Why the software stock sell-off may be bad news for private credit (Yahoo Finance Video)
10:40AM	Ares and Blue Owl Say They Had a Good 2025. The Stock Market Is Worried About 2026. (Barrons.com)
09:30AM	Ares Management (ARES) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:56AM	Ares (NYSE:ARES) Misses Q4 CY2025 Sales Expectations (StockStory)
07:30AM	Loading…
07:30AM	Ares Management (ARES) Q4 Earnings and Revenues Miss Estimates (Zacks)
06:37AM	Ares Management: Q4 Earnings Snapshot (Associated Press Finance)
06:30AM	Ares Announces Record Fourth Quarter and Full-Year 2025 U.S. Direct Lending Origination Activity (ACCESSWIRE)
06:00AM	Ares Management Corporation Reports Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-04-26 12:05PM	Ares Capital Reports Earnings With Private Credit Under Pressure (Barrons.com)
09:56AM	Heard on the Street: A Bad Time for Private Credits Trust-Me Numbers (The Wall Street Journal)
07:00AM	Ares Capital Corporation Announces December 31, 2025 Financial Results and Declares First Quarter 2026 Dividend of $0.48 Per Share (Business Wire)
03:26AM	Heard on the Street Tuesday Recap: Code Red (The Wall Street Journal)
Feb-03-26 10:04PM	Earnings To Watch: Ares (ARES) Reports Q4 Results Tomorrow (StockStory) -10.15%
05:14PM	Heard on the Street Recap: Code Red (The Wall Street Journal)
05:08PM	Private Equity Stocks Tumble On Software Rout - Expert Warns Of New 'Cockroaches' (Benzinga)
04:38PM	Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit (Barrons.com)
03:46PM	AI Disruption Fears Roil Software Industry, and the Stock Market (The Wall Street Journal)
02:04PM	Software Slump Drags Down Private-Fund Managers (The Wall Street Journal)
01:00PM	AI Fears Sink Shares of Private-Credit Fund Managers (The Wall Street Journal)
12:03PM	Loading…
12:03PM	3 Asset Management Stocks Set to Pull Off Earnings Beat in Q4 (Zacks)
11:48AM	Ares Management Set to Report Q4 Earnings: What's in the Cards? (Zacks)
09:15AM	Insights Into Ares Management (ARES) Q4: Wall Street Projections for Key Metrics (Zacks)
03:00AM	Ares Completes Acquisition of BlueCove to Launch Systematic Credit Strategy (Business Wire)
Feb-02-26 08:14PM	Analyst Report: Ares Management Corporation (Morningstar Research)
03:00PM	Elara Caring Secures New Strategic Investment from Ares and DaVita (Business Wire)
09:45AM	Here's Why Ares Management (ARES) is a Strong Growth Stock (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Finance Stocks Now (Zacks)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-30-26 04:00PM	Ares Capital Corporation Announces Tax Reporting Information for Calendar Year 2025 (Business Wire)
10:10AM	Janus Henderson Group plc (JHG) Q4 Earnings and Revenues Surpass Estimates (Zacks)
Jan-29-26 10:00AM	Ares Management (ARES) Earnings Expected to Grow: Should You Buy? (Zacks)
09:17AM	Top 5 Private Equity Holding Companies: Publicly Traded PE Titans (24/7 Wall St.)
07:40AM	Ameriprise Financial Services (AMP) Q4 Earnings and Revenues Surpass Estimates (Zacks)
06:30AM	Ares Leads $1.6 Billion Debt Financing to Support Suave Brands and Elida Beauty Merger to Create Evermark (Business Wire)
Jan-28-26 07:55AM	MSCI (MSCI) Q4 Earnings Beat Estimates (Zacks)
Jan-27-26 05:00PM	Ares Management Corporation to Present at the Bank of America Securities 2026 Financial Services Conference (ACCESSWIRE)
Jan-23-26 08:55AM	How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings (Zacks)
Jan-21-26 09:00PM	Private-Credit Investors Are Cashing Out in Droves (The Wall Street Journal)
03:15PM	Despite Credit Fears, Private Asset Managers Press On (Barrons.com)
Jan-20-26 01:14PM	OneDigital Adds Private Investments to DC Plan Program (Wealth Management)
Jan-17-26 07:00AM	Private credit investors pull $7bn from Wall Streets biggest funds (Financial Times)
Jan-15-26 08:55AM	How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings (Zacks)
07:34AM	Stephen Ross Sees California Billionaire Tax as Palm Beachs Gain (Bloomberg)
Jan-14-26 01:04PM	Elon Musk Net Worth Is So Large, He Could Buy Every MLB, NBA, NFL, NHL Team And Still Have $103 Billion Left (Benzinga)
09:09AM	Ryan Announces Minority Investment from Neuberger Berman Capital Solutions (Business Wire)
Jan-13-26 08:01AM	ENGIE and Ares Partnership Further Expands with Addition of 730 MW Portfolio of New U.S. Solar and Wind Assets (PR Newswire)
06:30AM	Ares Raises Over $7 Billion for Leading Credit Secondaries Strategy (Business Wire)
Jan-10-26 03:00PM	More Bonds Are Teetering on the Brink of Junk: Credit Weekly (Bloomberg)
Jan-09-26 12:38PM	Private Credits Biggest BDCs Grappling With Investor Exodus (Wealth Management)
Jan-08-26 12:18PM	Trump Targets Wall Street Homebuyers: Why BlackRock, Blackstone Are Feeling The Heat (Benzinga)
Jan-07-26 06:09AM	What You Need to Know Ahead of Ares Management's Earnings Release (Barchart)
Jan-06-26 12:55PM	Apollo Reports Q4 Preliminary Net Investment Income of $325M (Zacks)
Jan-05-26 05:10PM	Ares Capital Corporation Prices Public Offering of $750 Million 5.250% Unsecured Notes Due 2031 (Business Wire)
04:30PM	Ares Management Corporation Schedules Earnings Release and Conference Call for the Fourth Quarter and Full Year Ending December 31, 2025 (ACCESSWIRE)
Dec-31-25 06:47AM	Stock Market News for Dec 31, 2025 (Zacks)
Dec-24-25 12:00PM	New Mountain Asset Sale Shapes Up as a Test of Private Credit Market (Barrons.com)
11:16AM	Ares Management Eyes Buyout to Strengthen Private Equity Business (Zacks)
Dec-19-25 12:42PM	Billionaire Stephen Ross Just Landed Florida's Biggest Construction Loan (GuruFocus.com)
11:21AM	Steward Partners Lands $475M Investment from Ares (Wealth Management)
Dec-18-25 12:59PM	Ares Just Dropped $700M on Dirt and Steel in Virginia (GuruFocus.com)
06:30AM	Ares Makes Significant U.S. Data Center Investments in Northern Virginia (Business Wire)
Dec-17-25 11:00PM	3 Reasons ARES Has Explosive Upside Potential (StockStory)
10:37PM	Reflecting On Asset Management Stocks' Q3 Earnings: Ares (NYSE:ARES) (StockStory)
Dec-11-25 11:34PM	2 Growth Stocks with All-Star Potential and 1 We Turn Down (StockStory)
Dec-10-25 04:28PM	Ares Management CEO: We're not in an AI bubble (CNBC TV)
11:45AM	Ares Management CEO on S&P 500 inclusion: 'It's a real milestone for any company' (CNBC TV)
12:01AM	Ares Replaces Pop-Tarts Purveyor Kellanova on S&P 500 (The Daily Upside)
Dec-09-25 06:27PM	Podcast: Dow Industrials Fall Ahead of Fed Interest-Rate Decision (The Wall Street Journal) +7.27%
05:06PM	Stocks to Watch Tuesday Recap: Nvidia, AutoZone, PepsiCo, Campbell's (The Wall Street Journal)
03:05PM	Stocks to Watch Tuesday: Nvidia, AutoZone, PepsiCo, Campbells (The Wall Street Journal)
02:15PM	Ares (ARES) Stock Trades Up, Here Is Why (StockStory)
12:05PM	Ares to join the S&P 500, Sallie Mae stock plunges (Yahoo Finance Video)
10:49AM	Ares Stock Surges. It Went From S&P 500 Snub to Kellanova Sub. (Barrons.com)
10:37AM	Ares Stock Missed the S&P 500 Cut on Friday. Why It Was Added on Monday. (Barrons.com)
08:39AM	These Stocks Are Moving the Most Today: Nvidia, AMD, CVS Health, Ares, Toll Brothers, SailPoint, Home Depot, and More (Barrons.com)
06:09AM	Nvidia shares pare gains on chips-to-China uncertainty, and other early movers (MarketWatch)
06:01AM	These Stocks Are Moving the Most Today: Nvidia, AMD, Ares, Toll Brothers, Alexander & Baldwin, and More (Barrons.com)
05:33AM	Ares Stock Surges. Its Replacing Kellanova in the S&P 500. (Barrons.com)
05:30AM	Consumer Loans Are Getting Harder to Tally-and the Risks Harder to Gauge (The Wall Street Journal)
04:46AM	Stock Market Today: S&P 500, Dow Flat As Final Fed Meeting of 2025 Slated to Kick Off (TheStreet)
04:18AM	Stock Market Today: Dow, S&P 500 and Nasdaq steady as Fed decision looms; job openings data on tap; Nvidia shares up after chips-to-China report (MarketWatch)
Dec-08-25 06:04PM	This financial company was just added to the S&P 500, and its stock is surging (MarketWatch)
05:57PM	Ares Management Set to Join S&P 500; Sezzle and Vital Farms to Join S&P SmallCap 600 (PR Newswire)
05:51PM	S&P 500 Announces Ares Will Replace Kellanova Stock (Barrons.com)
10:44AM	Goldman Sachs Adds Red-Hot Gaming and Technology Stocks to December Conviction List (24/7 Wall St.)
Dec-05-25 05:53PM	Carvana, CRH, and Comfort Systems USA to Join S&P 500 (Barrons.com)
04:34PM	The S&P 500 Is Due to Rebalance on Friday. What Could Change. (Barrons.com)
06:30AM	Wall Street Races to Cut Its Risk From AIs Borrowing Binge (Bloomberg)
01:00AM	The New Private-Equity Billionaires Who Are Taking Over Wall Street (Barrons.com)

Ares Management Corp. engages in the provision of investment and consultancy services. It operates through the following segments: Credit Group, Private Equity Group, Real Assets Group, Secondaries Group, and Other. The Credit Group segment includes the management of strategies across the liquid and illiquid spectrum, direct lending, and Asia-Pacific. The Private Equity Group segment involves the categorization of investment strategies as corporate, special opportunities, and Asia-Pacific. The Real Assets Group segment focuses on equity and debt strategies across infrastructure investments. The Secondaries Group segment consists of investment in secondary markets, alternative asset class strategies, private equity, real estate, infrastructure, and credit. The company was founded by Michael J. Arougheti, David B. Kaplan, John H. Kissick, Antony P. Ressler, and Bennett Rosenthal in 1997 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sagati Aghili Naseem	General Counsel	Feb 04 '26	Sale	134.92	3,921	529,032	326,889	Feb 06 06:00 PM
NASEEM SAGATI AGHILI	Officer	Feb 04 '26	Proposed Sale	131.60	3,921	516,004		Feb 04 04:36 PM
Sagati Aghili Naseem	General Counsel	Jan 22 '26	Sale	161.84	1,849	299,239	254,671	Jan 26 06:22 PM
NASEEM SAGATI AGHILI	Officer	Jan 22 '26	Proposed Sale	162.34	1,849	300,167		Jan 22 04:34 PM
Arougheti Michael J	Co-Founder and CEO	Nov 26 '25	Sale	154.48	136,067	21,019,622	154,930	Dec 01 08:57 PM
Arougheti Michael J	Co-Founder and CEO	Nov 28 '25	Sale	156.15	98,673	15,408,069	56,257	Dec 01 08:57 PM
Arougheti Michael J	Co-Founder and CEO	Dec 01 '25	Sale	157.26	56,257	8,847,108	0	Dec 01 08:57 PM
Arougheti Michael J	Co-Founder and CEO	Nov 25 '25	Sale	152.75	186,197	28,442,509	290,997	Nov 25 09:15 PM
Arougheti Michael J	Co-Founder and CEO	Nov 24 '25	Sale	150.15	112,806	16,937,821	477,194	Nov 25 09:15 PM
ATTICUS ENTERPRISES LLC	Director	Nov 24 '25	Proposed Sale	147.43	590,000	86,983,700		Nov 24 04:27 PM
Sagati Aghili Naseem	General Counsel	Oct 01 '25	Sale	155.97	21,000	3,275,370	255,397	Oct 03 08:38 PM
NASEEM SAGATI AGHILI	Officer	Oct 01 '25	Proposed Sale	159.89	21,000	3,357,690		Oct 01 04:37 PM
Sagati Aghili Naseem	General Counsel	Sep 10 '25	Sale	178.40	21,000	3,746,321	276,397	Sep 12 07:34 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 10 '25	Sale	178.30	128,837	22,971,970	0	Sep 12 07:33 PM
ARES MANAGEMENT LLC	10% Owner	Sep 10 '25	Sale	1.13	13,000,000	14,710,800	41,197,491	Sep 11 04:31 PM
ARES MANAGEMENT LLC	10% Owner	Sep 09 '25	Sale	1.39	1,631,555	2,261,335	54,197,491	Sep 11 04:31 PM
TJ CAPITAL INVESTORS LLC	Director	Sep 10 '25	Proposed Sale	175.07	128,837	22,555,494		Sep 10 04:40 PM
NASEEM SAGATI AGHILI	Officer	Sep 10 '25	Proposed Sale	175.07	21,000	3,676,470		Sep 10 04:38 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 08 '25	Sale	175.78	170,341	29,942,945	230,237	Sep 09 09:42 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 09 '25	Sale	175.53	101,400	17,799,237	128,837	Sep 09 09:42 PM
TJ CAPITAL INVESTORS LLC	Director	Sep 09 '25	Proposed Sale	176.25	95,701	16,867,301		Sep 09 04:30 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 05 '25	Sale	177.05	176,784	31,300,367	400,578	Sep 05 08:37 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 04 '25	Sale	179.05	161,656	28,945,033	577,362	Sep 05 08:37 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 03 '25	Sale	176.76	126,499	22,359,617	739,018	Sep 05 08:37 PM
TJ CAPITAL INVESTORS LLC	Director	Sep 05 '25	Proposed Sale	180.05	300,000	54,015,000		Sep 05 04:38 PM
TJ CAPITAL INVESTORS LLC	Director	Sep 03 '25	Proposed Sale	179.78	300,000	53,934,000		Sep 03 04:33 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Sep 02 '25	Sale	178.61	177,929	31,780,770	865,517	Sep 02 08:27 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 29 '25	Sale	179.30	101,032	18,115,234	1,043,446	Sep 02 08:27 PM
TJ CAPITAL INVESTORS LLC	Director	Aug 29 '25	Proposed Sale	180.27	300,000	54,081,000		Aug 29 04:17 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 27 '25	Sale	180.23	171,686	30,943,111	1,252,852	Aug 28 08:05 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 28 '25	Sale	180.72	108,374	19,585,265	1,144,478	Aug 28 08:05 PM
TJ CAPITAL INVESTORS LLC	Director	Aug 27 '25	Proposed Sale	178.93	300,000	53,679,000		Aug 27 04:29 PM
Arougheti Michael J	Co-Founder and CEO	Aug 25 '25	Sale	178.19	44,760	7,975,789	0	Aug 26 09:39 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 26 '25	Sale	178.79	196,197	35,077,536	1,424,538	Aug 26 09:38 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 25 '25	Sale	178.08	112,522	20,037,464	1,620,735	Aug 26 09:38 PM
TJ CAPITAL INVESTORS LLC	Director	Aug 26 '25	Proposed Sale	178.13	196,197	34,948,572		Aug 26 04:26 PM
TJ CAPITAL INVESTORS LLC	Director	Aug 25 '25	Proposed Sale	181.07	112,522	20,374,359		Aug 25 04:38 PM
Arougheti Michael J	Co-Founder and CEO	Aug 22 '25	Sale	181.65	105,648	19,191,285	44,760	Aug 22 09:28 PM
Arougheti Michael J	Co-Founder and CEO	Aug 20 '25	Sale	178.39	97,880	17,461,120	213,848	Aug 22 09:28 PM
Arougheti Michael J	Co-Founder and CEO	Aug 21 '25	Sale	178.20	63,440	11,304,739	150,408	Aug 22 09:28 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 22 '25	Sale	181.65	105,394	19,144,739	1,733,257	Aug 22 09:28 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 20 '25	Sale	178.40	97,971	17,477,619	1,902,029	Aug 22 09:28 PM
RESSLER ANTONY P	Co-Founder & Exec. Chairman	Aug 21 '25	Sale	178.19	63,378	11,293,585	1,838,651	Aug 22 09:28 PM
TJ CAPITAL INVESTORS LLC	Director	Aug 20 '25	Proposed Sale	180.59	300,000	54,177,000		Aug 20 04:21 PM
Arougheti Michael J	Co-Founder and CEO	Aug 19 '25	Sale	182.74	136,516	24,946,638	311,728	Aug 19 08:49 PM
Arougheti Michael J	Co-Founder and CEO	Aug 18 '25	Sale	189.05	85,552	16,173,525	448,244	Aug 19 08:49 PM
Arougheti Michael J	Co-Founder and CEO	Aug 15 '25	Sale	188.69	56,204	10,604,893	533,796	Aug 19 08:49 PM
ATTICUS ENTERPRISES LLC	Director	Aug 18 '25	Proposed Sale	187.78	533,796	100,236,213		Aug 18 04:42 PM
ATTICUS ENTERPRISES LLC	Director	Aug 15 '25	Proposed Sale	190.45	56,204	10,704,052		Aug 15 04:24 PM
Rosenthal Bennett	Co-Founder & Chairman of PEG	Jun 12 '25	Sale	168.79	85,000	14,347,484	0	Jun 13 07:54 PM
ARES MANAGEMENT LLC	10% Owner	Jun 11 '25	Sale	8.86	2,250,000	19,928,025	117,449,188	Jun 13 04:32 PM
BAR HOLDINGS, LLC	Director	Jun 12 '25	Proposed Sale	168.78	85,000	14,346,300		Jun 12 04:20 PM
KAPLAN DAVID B	Co-Founder	May 30 '25	Sale	165.12	33,145	5,472,902	0	Jun 03 06:37 PM
KAPLAN DAVID B	Co-Founder	May 29 '25	Sale	165.06	23,524	3,882,871	33,145	May 29 08:59 PM
KAPLAN DAVID B	Co-Founder	May 28 '25	Sale	165.06	5,205	859,137	56,669	May 29 08:59 PM
KAPLAN DAVID B	Co-Founder	May 27 '25	Sale	165.07	626	103,334	61,874	May 29 08:59 PM
TRENTLY HOLDINGS, LLC	Officer	May 27 '25	Proposed Sale	160.29	62,500	10,018,125		May 27 04:32 PM
Arougheti Michael J	Co-Founder and CEO	May 20 '25	Sale	166.37	150,000	24,955,537	107,500	May 22 06:41 PM
Arougheti Michael J	Co-Founder and CEO	May 21 '25	Sale	161.34	107,500	17,344,225	0	May 22 06:41 PM
ARES MANAGEMENT LLC	10% Owner	May 16 '25	Sale	8.86	14,960,000	132,499,224	119,699,188	May 20 04:31 PM
Rosenthal Bennett	Co-Founder & Chairman of PEG	May 15 '25	Sale	169.37	40,000	6,774,878	85,000	May 19 08:18 PM
KAPLAN DAVID B	Co-Founder	May 15 '25	Sale	169.36	62,500	10,584,827	62,500	May 19 08:18 PM
Arougheti Michael J	Co-Founder and CEO	May 16 '25	Sale	170.07	182,108	30,971,183	350,684	May 19 08:17 PM
Arougheti Michael J	Co-Founder and CEO	May 19 '25	Sale	168.87	93,184	15,735,584	257,500	May 19 08:17 PM
Arougheti Michael J	Co-Founder and CEO	May 15 '25	Sale	169.55	57,208	9,699,584	532,792	May 19 08:17 PM
BAR HOLDINGS, LLC	Officer	May 15 '25	Proposed Sale	175.83	40,000	7,033,200		May 15 04:24 PM
TRENTLY HOLDINGS, LLC	Officer	May 15 '25	Proposed Sale	175.83	62,500	10,989,375		May 15 04:23 PM
ATTICUS ENTERPRISES LLC	Director	May 15 '25	Proposed Sale	175.83	590,000	103,739,700		May 15 04:22 PM
Arougheti Michael J	Co-Founder and CEO	Mar 24 '25	Sale	153.17	110,845	16,977,649	1,400,000	Mar 26 05:58 PM
MICHAEL J AROUGHETI	Officer	Mar 24 '25	Proposed Sale	147.71	110,845	16,372,915		Mar 24 04:22 PM
BHUTANI ASHISH	Director	Mar 11 '25	Buy	141.33	10,000	1,413,300	22,905	Mar 13 08:14 PM
Rosenthal Bennett	Co-Founder & Chairman of PEG	Mar 04 '25	Sale	161.01	69,809	11,239,742	30,191	Mar 06 09:06 PM
Rosenthal Bennett	Co-Founder & Chairman of PEG	Mar 05 '25	Sale	160.99	30,191	4,860,362	0	Mar 06 09:06 PM
KAPLAN DAVID B	Co-Founder	Mar 04 '25	Sale	160.99	69,526	11,192,960	30,474	Mar 06 08:57 PM
KAPLAN DAVID B	Co-Founder	Mar 05 '25	Sale	160.99	30,474	4,906,037	0	Mar 06 08:57 PM
TRENTLY HOLDINGS	Officer	Mar 04 '25	Proposed Sale	169.76	100,000	16,976,000		Mar 04 05:10 PM
BAR HOLDINGS, LLC	Officer	Mar 04 '25	Proposed Sale	169.76	100,000	16,976,000		Mar 04 05:10 PM

UTHR

United Therapeutics Corp

ARES

Ares Management Corp

Upgrade your FINVIZ experience